Aceragen, Inc. (ACGN) vs Jasper Therapeutics, Inc. (JSPR)

Aceragen, Inc. and Jasper Therapeutics, Inc. are both Biotechnology companies. Aceragen, Inc. and Jasper Therapeutics, Inc. are of similar size ($17.7M and $17.1M). Jasper Therapeutics, Inc. has the higher net margin (0.00% vs −467.5%) and the higher return on invested capital (0.00% vs −135.4%). Across the 13 metrics below, Jasper Therapeutics, Inc. leads on 7 and Aceragen, Inc. on 6.

Valuation

Metric ACGN JSPR Biotechnology median
P/E n/m n/m 8.50
P/S 1.52 n/m 9.71
P/B 0.83 9.75 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 4.09 n/m 9.21
Earnings yield (181.40%) (331.25%) (33.15%)
Free cash flow yield (250.88%) (437.42%) (25.50%)

Profitability

Metric ACGN JSPR Biotechnology median
Gross margin 83.46% 0.00% 65.16%
Operating margin (503.92%) 0.00% 0.00%
Net margin (467.53%) 0.00% 0.00%
Free cash flow margin (339.17%) 0.00% 0.00%
Return on equity (169.66%) (255.05%) (56.36%)
Return on assets (75.58%) (109.05%) (48.04%)
Return on invested capital (135.35%) 0.00% 0.00%

Growth

Metric ACGN JSPR Biotechnology median
Revenue growth (TTM) 1,226.28% — 6.02%
EPS growth (last fiscal year) (121.58%) 19.22% 30.26%
Revenue growth, 5-year CAGR 81.19% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACGN JSPR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.32 1.48 4.72
Net debt to EBITDA 0.43 0.35 0.96

Dividend

Metric ACGN JSPR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACGN JSPR Biotechnology median
Market cap 17.15m 17.70m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack